MACROGENICS, INC. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
MACROGENICS, INC. (MGNX) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2016-02-29
- MACROGENICS, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2015 was $0.00.
- MACROGENICS, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2014 was $0.00.
- MACROGENICS, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2013 was $0.00.
- MACROGENICS, INC. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2012 was $0.00.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |